| 1. |
- Stamatis, Pavlos, et al.
(författare)
-
Myocardial infarction in a population-based cohort of patients with biopsy-confirmed giant cell arteritis in southern Sweden
- 2024
-
Ingår i: RMD Open. - 2056-5933. ; 10:2
-
Tidskriftsartikel (refereegranskat)abstract
- Objectives To determine the incidence rate (IR) of myocardial infarction (MI), relative risk of MI, and impact of incident MI on mortality in individuals with biopsy-confirmed giant cell arteritis (GCA). Methods MIs in individuals diagnosed with GCA 1998-2016 in Skåne, Sweden were identified by searching the SWEDEHEART register, a record of all patients receiving care for MI in a coronary care unit (CCU). The regional diagnosis database, with subsequent case review, identified GCA patients receiving care for MI outside of a CCU. A cohort of 10 reference subjects for each GCA case, matched for age, sex and area of residence, was used to calculate the incidence rate ratio (IRR) of MI in GCA to that in the general population. Results The GCA cohort comprised 1134 individuals. During 7958 person-years of follow-up, 102 were diagnosed with incident MI, yielding an IR of 12.8 per 1000 person-years (95% CI 10.3 to 15.3). The IR was highest in the 30 days following GCA diagnosis and declined thereafter. The IRR of MI in GCA to that of the background population was 1.29 (95% CI 1.05 to 1.59). Mortality was higher in GCA patients who experienced incident MI than in those without MI (HR 2.8; 95% CI 2.2 to 3.6). Conclusions The highest incidence of MI occurs within the 30 days following diagnosis of GCA. Individuals with GCA have a moderately increased risk of MI compared with a reference population. Incident MI has a major impact on mortality in GCA.
|
|
| 2. |
|
|
| 3. |
- Stamatis, Pavlos, et al.
(författare)
-
Coronary Artery Disease in a Population-Based Cohort of Biopsy-Proven Giant Cell Arteritis in Southern Sweden
- 2019
-
Ingår i: Arthritis & Rheumatology. - : Wiley. - 2326-5205 .- 2326-5191. ; 71:Suppl 10
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- Background/Purpose: The aim of this study was to estimate the incidence rate and prevalence of coronary artery diseases (CAD) in patients with temporal artery positive giant cell arteritis (TAB+GCA) from a defined population in southern Sweden, and to describe characteristics of CAD in this sample.Methods: The study cohort consisted of 1202 patients (71.9% women) diagnosed with TAB+GCA between 1997 and 2016. Patients were identified from the database of the Department of Pathology which covers all the hospitals in the Skåne region of Sweden. The cohort was linked to the registry for acute coronary care (SWEDEHEART) which provides nationwide coverage since 1995. All the GCA patients with symptoms suggesting acute coronary syndrome who had been admitted to a coronary care unit (CCU) were identified. CAD was defined as an admission to a CCU for ST-Elevation Myocardial Infarction (STEMI), Non-ST-Elevation Myocardial Infarction (NSTEMI), stable angina, or unstable angina. For incidence rate analyses, the person-years of follow-up was calculated from GCA diagnosis until first CAD, death or December 31, 2016, whichever came first.Results: 126 of 1202 GCA patients had suffered at least one acute coronary event (Table 1) yielding the cumulative incidence of 10.5% (95% CI 8.7-12.3). Of the 126 patients with CAD, 44 (34.9%) were diagnosed with CAD before their GCA diagnosis, 11 (8.7%) both before and after their diagnosis, and 71 (56.3%) solely after their GCA diagnosis. The total number of CCU admissions of all the 126 GCA CAD+ patients was 209: 101 admissions (48.3%) for NSTEMI, 55 (26.3%) for stable angina, 29 (13.9%) for STEMI, and 24 (11.5%) for unstable angina. Eighty-two GCA patients (61% women) developed CAD after their diagnosis of GCA. During a total follow-up time of 8047 person-years, the incidence rate of CAD in patients with TAB+GCA was 1.0 per 100 person-years (95% CI 0.8-1.2) for all patients, 0.8 (95% CI 0.6-1.1) for women and 1.6 (95% CI 1.1-2.2) for men, p=0.02. Fifteen GCA patients suffered from a CAD event in 1156 person-years during the first year after the GCA diagnosis, resulting in an incidence rate of 1.3 per 100 person-years (95% CI 0.6-2.0). 703/1202 (58.5%) GCA patients were alive on December 31, 2016, of which 72 patients had at least one previous CAD event yielding a prevalence of CAD in GCA of 10.2%.Conclusion: The incidence of CAD in GCA is comparable to what has been previously found in the Swedish background population. The incidence rate is higher among men compared to women. Coronary artery disease affects every tenth patient with TAB+GCA in this cohort. Further studies are needed to explore the impact of CAD on clinical outcomes in patients with GCA.
|
|
| 4. |
- Desta, Liyew, et al.
(författare)
-
Adherence to beta-blockers and long-term risk of heart failure and mortality after a myocardial infarction
- 2021
-
Ingår i: ESC Heart Failure. - : Wiley. - 2055-5822. ; 8:1, s. 344-355
-
Tidskriftsartikel (refereegranskat)abstract
- Aims: The aim of this study is to investigate the association between adherence to beta-blocker treatment after a first acute myocardial infarction (AMI) and long-term risk of heart failure (HF) and death. Methods and results: All patients admitted for a first AMI included in the nationwide Swedish web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies register between 2005 and 2010 were eligible (n = 71 638). After exclusion of patients who died in-hospital, patients with previous HF, patients with unknown left ventricular ejection fraction (EF), and patients who died during the first year after the index event, 38 608 patients remained in the final analysis. Adherence to prescribed beta-blockers was determined for 1 year after the index event using the national registry for prescribed drugs and was measured as proportion of days covered, the ratio between the numbers of days covered by the dispensed prescriptions and number of days in the period. As customary, a threshold level for proportion of days covered ≥80% was used to classify patients as adherent or non-adherent. At discharge 90.6% (n = 36 869) of all patients were prescribed a beta-blocker. Among 38 608 1 year survivors, 31.1% (n = 12 013) were non-adherent to beta-blockers. Patients with reduced EF without HF and patients with HF with reduced EF were more likely to remain adherent to beta-blockers at 1 year compared with patients with normal EF (NEF) without HF. Being married/cohabiting and having higher income level, hypertension, ST-elevation MI, and percutaneous coronary intervention were associated with better adherence. Adherence was independently associated with lower all-cause mortality [hazard ratio (HR) 0.77, 95% confidence interval [CI] 0.71–0.84] and a lower risk for the composite of HF readmission/death, (HR 0.83, 95% CI 0.78–0.89, P value <0.001) during the subsequent 4 years of follow up. These associations were favourable but less apparent in patients with HFNEF and NEF. Conclusions: Nearly one in three AMI patients was non-adherent to beta-blockers within the first year. Adherence was independently associated with improved long-term outcomes; however, uncertainty remains for patients with HFNEF and NEF.
|
|
| 5. |
- Tjerkaski, Jonathan, et al.
(författare)
-
Comparison between ticagrelor and clopidogrel in myocardial infarction patients with high bleeding risk
- 2023
-
Ingår i: European Heart Journal - Cardiovascular Pharmacotherapy. - : Oxford University Press. - 2055-6837 .- 2055-6845. ; 9:7, s. 627-635
-
Tidskriftsartikel (refereegranskat)abstract
- Aims: Ticagrelor is associated with a lower risk of ischemic events than clopidogrel. However, it is uncertain whether the benefits of more intensive anti-ischemic therapy outweigh the risks of major bleeding in patients who have a high bleeding risk (HBR). Therefore, this study compared ticagrelor and clopidogrel in myocardial infarction (MI) patients with HBR.Methods and results: This study included all patients enrolled in the SWEDEHEART registry who were discharged with dual antiplatelet therapy using ticagrelor or clopidogrel following MI between 2010 and 2017. High bleeding risk was defined as a PRECISE-DAPT score & GE;25. Information on ischemic events, major bleeding, and mortality was obtained from national registries, with 365 days of follow-up. Additional outcomes include major adverse cardiovascular events (MACE), a composite of MI, stroke and all-cause mortality, and net adverse clinical events (NACE), a composite of MACE and bleeding. This study included 25 042 HBR patients, of whom 11 848 were treated with ticagrelor. Ticagrelor was associated with a lower risk of MI, stroke, and MACE, but a higher risk of bleeding compared to clopidogrel. There were no significant differences in mortality and NACE. Additionally, when examining the relationship between antiplatelet therapy and bleeding risk in 69 040 MI patients, we found no statistically significant interactions between the PRECISE-DAPT score and treatment effect.Conclusions: We observed no difference in NACE when comparing ticagrelor and clopidogrel in HBR patients. Moreover, we found no statistically significant interactions between bleeding risk and the comparative effectiveness of clopidogrel and ticagrelor in a larger population of MI patients.
|
|
| 6. |
- Wester, Axel, et al.
(författare)
-
Impact of Baseline Anemia in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention : A Prespecified Analysis From the VALIDATE-SWEDEHEART Trial
- 2019
-
Ingår i: Journal of the American Heart Association. - 2047-9980. ; 8:16, s. 012741-012741
-
Tidskriftsartikel (refereegranskat)abstract
- Background The impact of baseline anemia in a contemporary acute coronary syndrome (ACS) population undergoing percutaneous coronary intervention in the era of predominant radial artery access, potent P2Y12 inhibition, and rare use of glycoprotein IIb/IIIa inhibitors has not been adequately studied. Methods and Results ACS patients who underwent percutaneous coronary intervention between 2014 and 2016 in the VALIDATE-SWEDEHEART (Bivalirudin Versus Heparin in ST-Segment and Non-ST-Segment Elevation Myocardial Infarction in Patients on Modern Antiplatelet Therapy in the Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies Registry) trial without missing values for hemoglobin were included (n=5482). Mortality, myocardial reinfarction, and major bleeding at 180 days were assessed using Cox regression models and propensity score matching. All studied comorbidities were more common in ACS patients who had anemia (n=792). ACS patients with anemia had higher rates of 180-day mortality (6.9% versus 2.1%; hazard ratio, 1.9; 95% CI, 1.3-2.7; P<0.001), myocardial reinfarction (4.3% versus 1.9%; hazard ratio, 1.7; 95% CI, 1.1-2.7; P=0.013), and major bleeding (13.4% versus 8.2%; hazard ratio, 1.3; 95% CI, 1.0-1.6; P=0.041). The results were most evident in patients with a hemoglobin value <100 g/L, who had a nearly 10 times higher mortality rate. Conclusions Baseline anemia in ACS patients undergoing percutaneous coronary intervention, treated according to current practice including routine radial artery access, constitutes a high-risk feature for both ischemic events, bleeding events, and mortality. A multidisciplinary approach is warranted to maximize benefit and minimize patient risk. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT02311231.
|
|
